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Elevation of intracellular cyclic AMP (cAMP) levels has proven to be one of the most
effective means of overcoming inhibition of axonal regeneration by myelin-associated
inhibitors such as myelin-associated glycoprotein (MAG), Nogo, and oligodendrocyte
myelin glycoprotein. Pharmacological manipulation of cAMP through the administration
of dibutyryl cAMP or rolipram leads to enhanced axonal growth both in vivo and in vitro,
and importantly, upregulation of cAMP within dorsal root ganglion neurons is responsible
for the conditioning lesion effect, which indicates that cAMP plays a significant role in
the endogenous mechanisms that promote axonal regeneration. The effects of cAMP
are transcription-dependent and are mediated through the activation of protein kinase A
(PKA) and the transcription factor cyclic AMP response element binding protein (CREB).
This leads to the induction of a variety of genes, several of which have been shown to
overcome myelin-mediated inhibition in their own right. In this review, we will highlight
the pro-regenerative effects of arginase I (ArgI), interleukin (IL)-6, secretory leukocyte
protease inhibitor (SLPI), and metallothionein (MT)-I/II, and discuss their potential for
therapeutic use in spinal cord injury.
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Cyclic AMP: Overcoming Inhibition by Inducing Transcription
The identification of myelin-associated glycoprotein (MAG), Nogo, and oligodendrocyte
myelin glycoprotein as inhibitors of neurite outgrowth was a turning point in the
study of axonal regeneration, providing compelling evidence that CNS myelin proteins
contributed to regenerative failure after injury. Not surprisingly, their discovery sparked
great interest in developing experimental approaches to overcome this inhibition, and one
approach in particular has provided unique insight into the intrinsic mechanisms that
regulate axonal regeneration. Soon after the conditioning lesion effect was described by
Neumann and Woolf (1999), the laboratory of Dr. Marie T. Filbin demonstrated that
elevation of intracellular cyclic AMP (cAMP) levels through the administration of dibutyryl
cAMP (dbcAMP) reverses inhibition of neurite outgrowth by MAG and CNS myelin
(Cai et al., 1999). In subsequent studies it was shown that elevation of cAMP underlies
the conditioning lesion effect, as cAMP levels became elevated in dorsal root ganglia
(DRG) in response to a sciatic nerve lesion, and injection of dbcAMP directly into DRG
replicated the effects of a conditioning lesion on dorsal column axon regeneration (Neumann
et al., 2002; Qiu et al., 2002). The most important implication of these findings was that cAMP
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activates an intrinsic pro-regenerative program within the
neuron that allows it to overcome MAG- and myelin-mediated
inhibition at the molecular level.
Experiments aimed at characterizing this mechanism soon
revealed that the effects of cAMP were dependent on the
activation of protein kinase A (PKA), as administration of the
PKA inhibitor KT5720 abolished the ability of dbcAMP to
overcome inhibition by MAG (Qiu et al., 2002). One of the
primary downstream targets of PKA is the transcription factor
cyclic AMP response element binding protein (CREB), which is
phosphorylated at Ser133 and recruits the co-activator CREB-
binding protein (CBP)/p300, which in turn leads to initiation
of transcription by RNA polymerase II (Mayr and Montminy,
2001). Interestingly, there is evidence that like CREB, CBP/p300
activity can be regulated by PKA-mediated phosphorylation
(Vo and Goodman, 2001), and other kinases such as cyclin
E/Cdk2, calcium/calmodulin kinase IV, and mitogen-activated
protein kinase have also been shown to play a role in the
regulation of CBP/p300 (Vo and Goodman, 2001). CBP also
facilitates transcription through its histone acetyltransferase
activity, and it has been shown that histone hyperacetylation
mediated through inhibition of histone deacetylases enhances
neurite outgrowth for cerebellar neurons plated on CNS myelin
substrates (Gaub et al., 2010). This response is dependent
on CPB/p300 activity, as siRNA knockdown of this protein
abolished the ability of neurons to overcome inhibition by
CNS myelin, and it was also shown that CPB/p300 expression
is suppressed in the presence of myelin (Gaub et al., 2010).
Lastly it was shown that CPB/p300, together with p300-CBP-
associated factor (P/CAF), induces acetylation of p53 (Gaub
et al., 2010), which has been shown to form a signaling
complex with CPB and P/CAF and promote transcription
of genes with known roles in promoting axonal growth
(Di Giovanni et al., 2006; Tedeschi et al., 2009). The data
presented in these studies indicated that CBP and CREB-
mediated transcription play significant roles in overcoming
inhibition by CNS myelin, and these findings supported those
reported in an earlier study by Gao et al. (2004) which
showed that induction of CREB-mediated transcription is
required for cAMP to promote neurite outgrowth in the
presence of MAG, and that expression of constitutively active
CREB in DRG neurons is sufficient to enhance regeneration
of transected dorsal column axons. Having shown that the
effects of cAMP were transcription-dependent (Cai et al.,
2002; Gao et al., 2004), the work of the Filbin lab logically
progressed to the identification of the genes that were responsible
for mediating axonal regeneration. In this review, we will
highlight the four genes that have been studied to date:
arginase I (ArgI), interleukin (IL)-6, secretory leukocyte protease
inhibitor (SLPI), and metallothionein (MT), and discuss the
collective role of these and other genes in enhancing axonal
regeneration.
Arginase I
The first cAMP-regulated gene product to be investigated in
the context of MAG and myelin-mediated inhibition of neurite
outgrowth was ArgI, the rate-limiting enzyme of polyamine
synthesis (Cai et al., 2002). ArgI catalyzes the hydrolysis of
arginine to ornithine, which is converted to putrescine by
ornithine decarboxylase, and putrescine in turn is hydrolyzed to
spermidine and spermine (Munder, 2009). In cerebellar granule
neurons (CGN) treated with dbcAMP, levels of ArgI mRNA
and protein were visibly increased and this was accompanied
by a corresponding increase in putrescine synthesis. To assess
the importance of increased ArgI expression in enhancing
neurite outgrowth, ArgI was overexpressed in CGN using
adenoviruses and this allowed these neurons to extend neurites
on monolayers of MAG-expressing Chinese hamster ovary
(CHO) cells, which indicated that ArgI activity was sufficient to
mediate this response. Similarly, the role of polyamine synthesis
was investigated by administering two compounds that block
the synthesis of these molecules: N (omega)-hydroxynor-L-
arginine 5 (NOHA), an inhibitor of ArgI (Boucher et al., 1994),
and DL-2-difluor-omethyl-ornithine (DFMO), which inhibits
ornithine decarboxylase (Slotkin et al., 1982). Treatment with
either NOHA or DFMO abolished the ability of dbcAMP
to overcome inhibition by MAG and myelin, and this in
turn could be reversed by the addition of putrescine to the
cultured neurons, which suggested that polyamines were directly
responsible for promoting neurite outgrowth in the presence
of myelin-associated inhibitors. The first evidence to support
this was provided by experiments showing that putrescine
can overcome MAG inhibition either through direct addition
or through priming, a procedure in which the neurons were
treated overnight with putrescine prior to transferring them to
CHO cell monolayers (Cai et al., 2002). It was subsequently
shown that putrescine must be converted to spermidine to
have this effect, as treatment with the spermidine synthase
inhibitor bis-cyclohexylammonium sulfate (BCHS) blocked the
ability of putrescine to enhance neurite outgrowth (Deng
et al., 2009). Priming neurons with spermidine led to dose-
dependent increases in neurite outgrowth in the presence of
either MAG or myelin, and more importantly, regeneration
of retinal ganglion cell axons in the injured optic nerve was
significantly increased following a single intravitreal injection
of 20 µM spermidine (Deng et al., 2009). This conclusively
demonstrated that the products of ArgI activity can directly
promote axonal regeneration in vivo.
Interleukin-6
Expression of the pleiotrophic cytokine IL-6 was found to be
strongly induced by dbcAMP in DRG neurons in a microarray
performed in collaboration with Jason Carmel, then a member
of the laboratory of Dr. Ronald Hart (Cao et al., 2006). IL-6
is a member of the gp130 cytokine family, and other members
of this family such as leukemia inhibitory factor and ciliary
neurotrophic factor have been shown to have roles in promoting
axonal regeneration (Cafferty et al., 2001; Müller et al., 2007).
Delivery of IL-6 was found to promote both neurite outgrowth in
the presence of myelin-associated inhibitors and in vivo axonal
regeneration in the injured spinal cord (Cafferty et al., 2004; Cao
et al., 2006; Leibinger et al., 2013). Retinal ganglion cells (RGCs)
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can overcome inhibition by myelin following IL-6 treatment
and IL-6 has the added benefit of being neuroprotective,
which allowed intravitreal injection of IL-6 to promote axonal
regeneration after optic nerve crush (Leibinger et al., 2013).
Though this pro-regenerative function is an unexpected finding
for a pro-inflammatory cytokine, it brings up the intriguing
point that restricted inflammation maybe a positive factor in
promoting axonal growth. Though little has been elucidated
about IL-6’s mechanism of action, intravitreally injected IL-
6 was shown to elevate phosphorylation of signal transducer
and activator of transcription (STAT)-3 in the ganglion cell
layer (Leibinger et al., 2013). STAT-3 activation triggers neurite
outgrowth in both PC-12 and Neuro2A cells (Ihara et al., 1997;
Zorina et al., 2010) and overexpression of STAT-3 in RGCs
promotes regeneration when an optic nerve crush is performed
in combination with lens injury (Leibinger et al., 2013). The
latter suggests that STAT-3 alone is not sufficient to promote
axonal regeneration and that additional stimuli are required.
Hence, further elucidation of the mechanisms and downstream
pathways involved with IL-6 dependent axonal regeneration
could lead us to potential targets that could promote regeneration
without exacerbating the hyper-inflammatory response that is
elicited after injury to the CNS.
Secretory Leukocyte Protease Inhibitor
The same microarray that identified IL-6 also showed that
expression of SLPI was increased 3.9-fold in response to elevation
of cAMP, and subsequent quantitative real-time PCR analysis
of these samples revealed an 8.5-fold increase in SLPI mRNA
levels (Hannila et al., 2013). These results were later confirmed
in experiments that showed that SLPI mRNA levels were
significantly increased following either exposure to dbcAMP or
a peripheral conditioning lesion (Hannila et al., 2013). While
SLPI was one of the most highly expressed genes identified in
the microarray, its role promoting in neurite outgrowth was not
immediately apparent, as SLPI is serine protease inhibitor best
known for its anti-microbial, and anti-inflammatory functions.
These include inhibiting the growth of bacteria, blocking
HIV infection of monocytes/macrophages, and inhibiting the
expression of the pro-inflammatory cytokines such as tumor
necrosis factor α. In the CNS, elevated expression of SLPI has
been observed in response to cerebral ischemia, and in a study
by Wang et al. (2003), infarct volume was significantly reduced
when SLPI was adenovirally overexpressed prior to middle
cerebral artery occlusion. SLPI expression was also strongly
upregulated following spinal cord contusion injury in mice,
and administration of recombinant SLPI produced significant
improvement in locomotor function, as well as increased tissue
preservation and axonal density, in these animals (Ghasemlou
et al., 2010). The findings of these studies have led to the
hypothesis that SLPI is neuroprotective, and this has now
been complemented by our work showing that SLPI has pro-
regenerative effects as well.
In neurite outgrowth assays, neonatal DRG and cortical
neurons treated with SLPI were able to overcome inhibition
by MAG and myelin, and adult DRG neurons that received
intrathecal delivery of SLPI showed enhanced neurite outgrowth
in the presence of MAG compared to neurons that received
infusions of sterile saline (Hannila et al., 2013). To provide
definitive proof that SLPI could overcome inhibition by CNS
myelin in vivo, a single intravitreal injection of SLPI (10 µg) was
administered to adult rats immediately after optic nerve crush.
When axonal regeneration was assessed 2 weeks later, there was
a significant increase in axonal density distal to the lesion site
in animals that received SLPI, which indicated that SLPI can
promote axonal regeneration in the injured mammalian CNS.
The importance of SLPI in axonal regeneration is also
demonstrated by its role in the conditioning lesion effect.
When compared to wild type mice, SLPI null mutant mice
displayed significantly less regeneration of dorsal column axons
in response to a sciatic nerve lesion (Hannila et al., 2013).
This indicated that SLPI is required for this response, and the
underlying mechanism can be tied to the expression of Smad2,
an intermediate in the transforming growth factor β signaling
pathway that is essential for mediating inhibition by CNSmyelin.
Smad2 can be effectively knocked down using siRNA, leading to
increased neurite outgrowth on myelin, and both dbcAMP and
sciatic nerve lesions have similar effects, producing significant
reductions in Smad2 levels within 18–24 h. In SLPI null mutant
mice that received a sciatic nerve lesion, Smad2 expression was
unaffected, which indicated that the ability of cAMP to reduce
Smad2 is SLPI-dependent. It was also shown that SLPI is capable
of rapidly localizing the nuclei of neurons and binding to the
promoter for Smad2 with a high degree of specificity, which led
us to conclude that cAMP induces expression of SLPI and that
SLPI then facilitates axonal growth by blocking transcription of
the Smad2 gene and reducing the amount of Smad2 available
to mediate inhibition. It is therefore likely that both SLPI
and Smad2 could prove to be viable targets for therapeutic
intervention in spinal cord injury.
Metallothionein
MT were first identified nearly 60 years ago, are found in
all cells of the body, and though they have been extensively
studied, have a poorly defined physiological role. They are
distinguished by their small size (approximately 6–7 kD) and
abundance of cysteines (20 residues) which coordinate binding
of up to seven divalent cationic metals, such as zinc, copper or
cadmium (Chung et al., 2008). It is this metal binding ability
that has often led to them being labeled as simple chelators of
excessive non-protein bound zinc or copper. However, several
reports have supported a more selective role for MT in that
they could modulate the activity of zinc-dependent proteins,
such as transcription factors, by either donating or removing the
zinc moiety (Zeng et al., 1991). There are four isoforms of MT:
MT-I, -II, -III and -IV; and of these isoforms only MT-IV is
not found in the CNS. MT-I and -II are two very closely related
isoforms and they are often co-expressed. It is the astrocytes that
predominantly expressMTs and have been shown to secreteMTs
in response to injury (West et al., 2008; Miyazaki et al., 2011).
Neurons also express MTs, but at levels that are 2–3 fold lower
than glial cells. Extensive studies have been conducted in the
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nervous system of MT-deficient mice, and these have shown that
MT-deficient mice display extremely poor outcomes in models
of stroke, seizures, and multiple sclerosis (Carrasco et al., 2000;
Penkowa et al., 2001; Trendelenburg et al., 2002). It was through
these studies that a neuro-protective role for MTs in the CNS
was suggested, and it is believed that MT mediates this effect
by scavenging reactive oxygen species (Penkowa et al., 2000;
Kondoh et al., 2001).
In our microarray analysis, we observed a significant increase
in expression of MT-I/II following either dbcAMP treatment in
neonatal DRG neurons or a conditioning lesion in adult DRGs
(Siddiq et al., 2015). Though MT-I/II levels have been shown to
be elevated in response to divalent metals and glucocorticoids,
it was intriguing to see that it was induced in response to
elevated levels of cAMP. Though the promoter of MT-I/II lacks
a clear cAMP response element, there are several IL-6 response
elements. It is therefore possible that the cAMP-dependent
increase in IL-6 levels subsequently leads to elevated expression
of MT-I/II, and this is supported by the fact that IL-6-deficient
mice display reduced expression of MT-I/II after injury to the
CNS (Penkowa et al., 2000).
In our study, MT-I/II applied to primary neurons can
overcome MAG- or myelin-mediated inhibition and MT-I/II-
deficient mice have an attenuated response to conditioning
lesion compared to wild-type littermates (Siddiq et al., 2015).
Intravitreal injection of MT-I/II also promotes modest axonal
regeneration following optic nerve crush, and this pro-
regenerative effect is amplified with lens injury (Siddiq et al.,
2015), which implies that a combination of MT-I/II and other
regeneration-associated genes are required for robust axonal
regeneration. Mechanistically, zinc chelation had no effect on
myelin-mediated inhibition of neurite outgrowth, suggesting that
this was not the source of MT-I/II’s effects (Siddiq et al., 2015).
However, MT-I/II directly inhibited the activity of α-secretase,
and it also blocked MAG-induced phosphorylation of protein
kinase C and activation of the small GTPase RhoA (Siddiq et al.,
2015), which suggests that MT-I/II enhances axonal regeneration
by interfering with the downstream signaling pathways activated
by myelin-associated inhibitors.
Summary
It has become increasingly clear that there is no single
pathway, protein, or drug that can promote robust axonal
regeneration in the injured CNS, but our microarray analysis
of the conditioning lesion effect has provided us with valuable
insight into the spectrum of genes that are modulated to
produce axonal regeneration. In the case of ArgI, IL-6, SLPI,
and MT-I/II, each protein can overcome inhibition by myelin
and promote modest axonal regeneration, but all four have
uniquely different mechanisms for overcoming the inhibitory
environment of the CNS (Figure 1). Another gene that is
likely contributing to the conditioning lesion effect is brain-
derived neurotrophic factor (BDNF). Like the genes identified
in the microarray, BDNF expression is regulated by cAMP
and CREB (Finkbeiner et al., 1997), and BDNF has been
shown to significantly enhance survival of axotomized neurons
FIGURE 1 | Schematic representation of cAMP-induced gene
expression that has been shown to overcome inhibition by CNS
myelin. Elevation of intracellular cAMP leads to activation of protein kinase A
(PKA), and transcription of the ArgI, IL-6, SLPI, and metallothioneins (MT)-I/II
genes by phosphorylated CREB. The products of these genes then reverse
myelin-induced inhibition of neurite outgrowth through their own distinct
mechanisms.
following spinal cord injury, and promote axonal sprouting and
regeneration (Kobayashi et al., 1997; Kwon et al., 2002). To
develop effective treatments for spinal cord injury, it will be
necessary to examine the combinatorial effects of IL-6, ArgI,
SLPI and/or MT-I/II, as well as other growth-promoting agents
such as BDNF, and optimize the dosages to achieve synergistic
effects.
In the microarray, we also identified other genes that are
upregulated in response to elevated cAMP, such as fibulin
5, superoxide dismutase 3, nerve growth factor inducible
protein (VGF), and lactate dehydrogenase A (full microarray
results available at http://genome.rutgers.edu/slpi/, Hannila
et al., 2013), and their roles in axonal growth have not yet
been explored. It should also be noted that numerous genes
were significantly down-regulated, such as insulin-like growth
factor-binding protein 5, monocyte chemoattractant protein-
1, and intriguingly, MT-III (Hannila et al., 2013),1 which
has been suggested to be inhibitory to neurite outgrowth
(Uchida et al., 1991). This suggests that cAMP may not only
upregulate the expression of growth-promoting genes, but also
limit the expression of genes that negatively impact axonal
regeneration. By continuing to investigate the effects of these
cAMP-regulated genes on axonal growth, we will advance
our understanding of endogenous repair mechanisms, move
1http://genome.rutgers.edu/slpi/
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closer to the ultimate goal of developing methods to enhance
them and produce clinical benefit for patients with spinal cord
injury.
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